Management of IgA nephropathy: Evidence-based recommendations  by Nolin, Linda & Courteau, Maryse
Kidney International, Vol. 55, Suppl. 70 (1999), pp. S-56–S-62
Management of IgA nephropathy:
Evidence-based recommendations
LINDA NOLIN and MARYSE COURTEAU
Division of Nephrology, Hoˆpital Maisonneuve-Rosemont and Division of Nephrology, Centre Hospitalier de l’Universite´ de
Montre´al, Montreal, Quebec, Canada
Management of IgA nephropathy: Evidence-based recommen- glomerular diseases, whereas in Europe, it has been re-
dations. The condition known as IgA nephropathy was first ported in 10 to 30% of glomerular disease series [8]. In
identified when Berger observed mesangial staining for IgA in the United States, the overall prevalence is approxi-healthy patients with isolated hematuria. These patients often
mately 10 to 15% [9], although in specific groups suchpresented with recurrent synpharyngitic hematuria or less fre-
as the American Indians in the Southwest, the rate isquently with asymptomatic microscopic hematuria and protein-
uria. Although initially considered benign, we now recognize 35% [10]. IgAN is uncommon in blacks, whether they
it as a common cause of end-stage renal failure. The overall live in the United States or in Africa [11, 12].
prognosis may be better than suggested in the literature, as Recurrence of IgAN after transplantation [13], evi-patients with mild asymptomatic hematuria are often not biop-
dence showing that IgA glomerular deposits disappear insied and, therefore, frequently are not included in published
a kidney from an IgA donor [14], and IgA deposits ob-articles. We reviewed prospective and retrospective adult studies
published after 1976 and analyzed them to produce evidence- served in other organs such as skin, lungs [15], or intes-
based recommendations. Patients with proteinuria over 3 g/day, tines suggest that the basic abnormality in this disease
mild glomerular changes only, and preserved renal function
lies within the IgA immune system. IgAN patients have(creatinine clearance over 70 ml/min) should be treated with
been shown to have many humoral and cellular abnor-prednisone. Steroids reduce proteinuria (grade B recommen-
dation) and stabilize kidney function (grade C). The combina- malities that possibly contribute to IgA deposition in the
tion of cyclophosphamide, dipyridamole and warfarin should glomerulus [16, 17]. Fifty percent have an increase in
not be used (grade A), nor should cyclosporine A (grade B). serum IgA at some time in the course of the disease,In patients with progressive disease (creatinine clearance of
which is mainly polymeric, with a shift in subclass towardless than 70 ml/min), fish oil should be given (grade B). A
IgA1 as found in their kidney eluates [18]. High levelstonsillectomy could reduce proteinuria and hematuria in those
patients with recurrent tonsillitis (grade D). Those with hyper- of circulating immune complexes are detected, and their
tension should be treated promptly with an angiotensin-con- presence correlates with the intensity of hematuria [19].
verting enzyme inhibitor (grade B).
This article analyzed the studies published according
to their level of evidence, and based the grade of recom-
mendations on the evidence (Fig. 1).
IgA nephropathy (IgAN) or Berger’s disease was first
described in the late 1960s [1]. It is characterized by Natural history
prominent and diffuse IgA deposits in the glomerular
The natural history of IgAN is quite variable. In upmesangium on immunofluorescent microscopy [2, 3]. Al-
to 23% of reported series, complete remissions occur,though there are many secondary causes of IgA deposi-
even though spontaneous disappearance of immuno-tion in the mesangium, such as hepatic cirrhosis [4], en-
fluorescent IgA-staining mesangial deposits has not beenteropathy [5], arthritis, dermatitis herpetiformis, and
described.Henoch-Scho¨nlein purpura [6], their treatment is not
In terms of renal function, IgAN patients most oftendiscussed in this review.
follow a benign course. In those patients who do showIgA nephropathy is now considered the most common
progressive renal impairment, this usually takes manyglomerular disease worldwide [7]. In Asia, particularly in
years. In 1991, Rekola, Bergstrand, and Bucht reportedJapan, this condition accounts for one half of all primary
a rate of loss of glomerular filtration rate (GFR) averag-
ing 1 to 3 ml/min/year among patients with normal GFR
at presentation and up to 9 ml/min/year among nephroticKey words: Berger’s disease, nephrotic syndrome, glomerular mesan-
gium, immunoglobulin A, hematuria, proteinuria. patients [20]. End-stage renal disease (ESRD) developed
in 20% of cases after 10 years and in 30% after 20 years, 1999 by the International Society of Nephrology
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Fig. 1. Decision tree for biopsy-proven IgA ne-
phropathy (IgAN). Blood pressure in all cases
should be controlled with angiotensin con-
verting enzyme inhibitors (ACEI).
whereas another 30% showed some decline in renal func-
tion [20].
In 1994, Ibels and Gyory reported a slower decline in
121 patients [21]. Their cumulative probability of renal
survival after presentation and biopsy was 93% at 5 years
and 86% at 10 years. These results were not in accor-
dance with other studies and did not agree with the
observation that IgAN was the cause of ESRD in 41% of
patients with primary glomerulonephritis in Australasia.
Discrepancies in these reported outcomes could be due
to different referral patterns, indications for biopsy or Fig. 2. Decision tree for biopsy-proven IgA nephropathy (IgAN) with
management policies during follow-up, or to racial differ- a rapidly progressive course.
ences in the severity of disease activity [21].
Acute renal failure in IgAN may be secondary to acute
tubular necrosis following macroscopic hematuria and
incidence of hypertension, and lower prevalence of mac-upper respiratory tract infection [22] or associated with
roscopic hematuria.extensive crescent formation, focal necrotizing lesions,
Finally, a favorable prognosis has been reported whenor severe tubulointerstitial disease [11]. These conditions
recurrent macroscopic hematuria occurs in an infection-should be promptly identified by biopsy (Fig. 2).
associated exacerbations of disease activity. These pa-
tients are usually younger and have less hypertensionPrognostic factors
and no proteinuria between episodes [21].
The degree of impairment in renal function at presen-
tation is an important predictor of a poor outcome [23]. It
METHODSis often associated with unfavorable renal biopsy findings
such as glomerular sclerosis, tubulointerstitial atrophy The English and French literature published on the
or fibrosis, and scarring. Crescentic presentation is rare treatment of IgAN since 1976 has been reviewed. Sur-
and carries a bad prognosis [24]. Proteinuria in the ne- prisingly few clinical trials focused on the therapy of this
phrotic range also predicts a poor prognosis [25], as does most common glomerular disease. This paucity may be
the initial presence or the development of high blood explained by the fact that for many years, the natural
course of the disease has been believed benign and mostpressure. Older patients have worse outcomes, increased
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Table 1. Corticosteroids
Author Follow-up Level of
[Reference] Design N Treatment months Results P value evidence
Lai [27] RCT 34 Daily 38 Renal function 5 ,0.01 1
4 months proteinuria ↓
Kobayashi [28] NCT 29 Daily 47 Natural course 5 4
12–36 months proteinuria ↓
Kobayashi [29] NRCT 46 Daily 120 Renal function ↑ ,0.05 3
18 months proteinuria ↓
in one subgroup
Abbreviations are: RCT, randomized controlled trial; NCT, non-controlled trial; NRCT, non-randomized controlled trial.
of the recent work focused on the pathogenesis of the in IgAN patients (grade A recommendation). Cyclospor-
ine A (CsA) should not be used (grade B).disease [26].
Evidence. Two level 1 studies examined therapy using
Recommendations the combination of cyclophosphamide, dipyridamole,
and warfarin (Table 2). Although Woo et al initiallyRecommendation 1. Patients with mild histopatholog-
ical changes, proteinuria over 3 g/day, and preserved demonstrated reduction of proteinuria and stabilization
of renal function [30], a five-year post-trial assessmentrenal function (creatinine clearance over 70 ml/min)
should be treated with prednisone for four to six months. found no difference in renal function between the treat-
ment and control groups [31]. Walker et al showed noAn initial dose of 1 mg/kg/day is recommended, with
alternate day administration and gradual tapering after statistical difference in renal function in their trial, but
did show a reduction in proteinuria in the treated groupeight weeks in responsive patients. Steroids reduce pro-
teinuria (grade B recommendation) and stabilize kidney [32]. In these studies, there were no histological evalua-
tions after treatment. Gonadal function was reduced,function (grade C).
Evidence. Prednisone given on a daily or alternate making this treatment unacceptable in young patients.
As a variety of immunologic abnormalities suggestday basis has had variable results in IgAN. Three studies
have been published in adults with IgAN (Table 1). In that IgAN is an autoimmune disorder, CsA was used by
Lai, Lai, and Li in a randomized single-blind trial (levelLai’s 1986 prospective randomized control trial, 17 pa-
tients were treated with daily oral steroids for four 2), shown in Table 3 [33]. The drug was used with a
plasma cyclosporine target level of 50 to 100 mg/ml inmonths and compared with 17 controls. During the mean
study period of 38 months, no significant difference in 24 patients who had proteinuria at least 1.5 g/day and a
diminished creatinine clearance, who were treated forcreatinine clearance was demonstrated between the two
groups. Corticosteroid treatment resulted in a high rate 12 weeks. They showed a significant fall in protein excre-
tion, accompanied, however, by a rise in serum creati-of remission of nephrotic syndrome among patients with
mild glomerular histopathological changes, but many ex- nine. These changes were reversed after cessation of
treatment.perienced side-effects. This level 1 study suggests that
steroid therapy is only beneficial in selected patients with Recommendation 3. In patients with a slow progres-
sive decline in creatinine clearance (less than 70 ml/min),nephrotic syndrome and minor grade histology [27].
In 1988, Kobayashi et al reported a retrospective study fish oil should be given (grade B recommendation).
Evidence. Deficiencies of essential fatty acids have(level 4) of 29 patients with proteinuria over 2 g/day who
were given daily prednisone for 12 to 36 months. Steroids been detected in IgAN [34], and fish oil may favorably
influence the disease by acting on potential mediatorsstabilized kidney function in the subgroup with pre-
served initial creatinine clearance (over 70 ml/min). Un- that stem from the initial glomerular injury. Fish oil is
rich in long-chain omega-3-polyunsaturated fatty acidsfortunately, no definitive conclusion can be drawn from
this uncontrolled study [28]. (v-3-PUFA), eicosapentaenoic acid (EPA), and docosa-
hexaenoic acid (DHA). These can replace arachidonicThe same authors published a prospective controlled
study in 1996 in which a subgroup of the 1988 study was acid and act as substrates for both lipoxygenase and
cyclooxygenase enzymes, resulting in the production ofcompared with an untreated group. Daily steroids for
18 months showed a protective effect on renal function altered and biologically less effective prostaglandins and
leukotrienes, changes in membrane fluidity, and reducedand a reduction in proteinuria 10 years after therapy
(level 3) [29]. platelet aggregability [35]. The first clinical report was a
preliminary article by Hamazaki, Tateno, and ShishidoRecommendation 2. The combination of cyclophos-
phamide, dipyridamole, and warfarin should not be used in 1984 involving 20 IgAN patients. The treatment group
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Table 2. Cyclophosphamide, dipyridamole, and warfarin
Follow-up Level of
Author [Reference] Design N Treatment months Results P value evidence
Woo [30] RCT 48 Cyclophosphamide 6 months 36 Proteinuria ↓ ,0.01 1
and renal function ↑
Follow-up study [31] Dypiridamole, warfarin 36 months 96 No difference
Walker [32] RCT 52 Cyclophosphamide 6 months and 24 Renal function 5 , 0.01 1
dypiridamole, warfarin 24 months proteinuria ↓
The abbreviation is: RCT randomized controlled trial.
Table 3. Cyclosporine
Follow-up Level of
Author [Reference] Design N Treatment months Results P value evidence
Lai [33] RCT 24 Cyclosporine 6 months 15 Proteinuria ↓ ,0.05 2
renal function ↓
The abbreviation is: RCT, randomized controlled trial.
Table 4. Fish oil
Follow-up Level of
Author [Reference] Design N Treatment months Results P value evidence
Bennett [37] RCT 37 EPA-DHA 24 No benefit on kidney function 1
1.8 g–1.2 g daily
Pettersson [35] RCT 32 EPA-DHA 6 Renal function ↓ 1
3.3 g–1.8 g proteinuria 5
Donadio [38] RCT 106 EPA-DHA 24 Slow the progression of kidney failure 50.002 1
1.8 g–1.2 g
Cheng [39] Before and 11 EPA-DHA 10 No benefit on kidney function 4
after study 1.8 g–1.2 g
Abbreviations are: RCT, randomized controlled trial; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
who received fish oil for a year maintained a stable renal fish oil group and 33% in the placebo group reached
the end point at two years (P 5 0.002), whereas thefunction as opposed to untreated controls, who displayed
deterioration of the reciprocal of serum creatinine [36]. cumulative percentage of ESRD was 40% in the placebo
group after four years and 10% in the fish oil group (P 5Three level 1 studies have been published and are
summarized in Table 4. Bennett, Walker, and Kincaid- 0.006). There was a minimal effect on proteinuria. No
patient stopped treatment because of adverse effects. InSmith in 1989 published a two-year prospective trial
showing no definite benefit of EPA in the kidney func- this study by Donadio et al, fish oil slowed the rate of
decline in GFR [38].tion of 37 patients. At the end of the trial, creatinine
clearance in 17 treated patients went from 80 to 57 ml/ Cheng, Chan, and Chan, in 1990, reported a level 4
study on 11 IgAN patients treated with fish oil supple-min, and in 20 untreated patients, it went from 76 to 55
ml/min [37]. ments. The reciprocal of the serum creatinine before and
after treatment was compared. Treatment had either anPettersson et al in 1994 reported a six-month prospec-
tive, randomized study in 32 patients: 15 assigned to fish undemonstrable or an unpredictable effect [39].
An ongoing randomized study is evaluating the effectoil with a high percentage of v-3-PUFA and 17 to corn
oil [35]. By six months, fish oil administration resulted of alternate-day prednisone versus daily fish oil supple-
ments versus placebo, on the decline of renal functionin a slight but significant reduction in creatinine clear-
ance (63 to 59 ml/min), whereas no change occurred in in young patients with moderately severe IgAN [40].
Recommendation 4. There are insufficient data at thisthe control group. The proteinuria remained unchanged.
The third published trial was a multicenter, placebo- stage to recommend the use of azathioprine and predni-
sone in IgAN patients.controlled, randomized trial in 55 patients treated with
12 g daily of fish oil and 51 controls receiving olive oil Evidence. In the adult literature, only one study has
been published examining the use of azathioprine and[38]. The primary end point was an increase of 50% or
more in the baseline serum creatinine. Six percent in the steroids (Table 5). Goumenos et al published a retrospec-
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Table 5. Azathioprine and steroids
Follow-up Level of
Author [Reference] Design N Treatment months Results P value evidence




Abbreviations are: NRCT, non-randomized controlled trial; Retro, retrospective study.
tive trial in 1995 that used azathioprine and prednisolone
in 66 patients. They showed that this regimen can be
beneficial in slowing the progression of IgAN compared
with 48 untreated patients [41]. However, in this level 4
study, the treated patients had more severe histological
changes at presentation, and the decision to treat was
based on these changes. Controlled trials are needed to
confirm these data before this treatment can be recom-
mended.
Recommendation 5. In IgAN patients with rapidly
progressive disease, an evidence-based treatment cannot
be recommended at this stage.
Fig. 3. Decision tree for IgA proven nephropathy with macroscopic
Evidence. The rapidly progressive form of IgAN is hematuria.
fortunately rare. The clinical course is characterized by
a decrease in GFR of 50% or more within a three-month
period and is usually associated with crescents on biopsy.
strated on kidney function, in 34 patients with recurrentIn adults with this type of disease, only a few studies
infections (level 5) [45]. Tonsillectomy might be recom-with small numbers of patients have been published.
mended in those patients showing recurrent macroscopicTwo authors reported good results with plasmaphere-
hematuria episodes in conjunction with tonsillitis.sis in stabilizing patients during the acute phase of the
Recommendation 7. In patients with IgAN, hyperten-disease; however, these reports were anecdotal and un-
sion should be treated promptly, if possible, with ancontrolled [42, 43]. In 1995, Roccatello et al reported a
angiotensin-converting enzyme inhibitor (grade B).combined treatment with pulse steroids, cyclophospha-
Evidence. High blood pressure is an important nega-mide, and plasma exchanges in six patients with at least
tive prognostic marker in IgAN and should be treated40% crescents. They compared the results with those
early in the course of the disease [46]. It has been shownobtained in three untreated patients. The repeated biopsy
that angiotensin II has a direct hypertrophic action onshowed persistence of acute crescents in the majority of
several cells, including the glomerular cells, and may beaffected glomeruli, but three patients were not on dialysis
an important factor in the initiation of sclerosis [47]. Itafter five years compared with the untreated group
can also encourage sclerosis by promoting extracellularwhere two patients were dialyzed and one dead after
matrix component release, as demonstrated in culturedthree years [44].
mesangial cells.Recommendation 6. Tonsillectomy might be benefi-
In a study of patients with moderate renal impairment,cial in IgAN patients with recurrent tonsillitis (grade D;
the administration of angiotensin-converting enzymeFig. 3).
inhibitors produced more favorable and pronouncedEvidence. The macroscopic hematuria seen in IgAN,
changes in the decrease of filtration fraction, comparedwhich is commonly precipitated by a mucosal stimulation
with those found in patients with normal renal function(pharyngitis, gastroenteritis), could be explained by a
and healthy controls (Table 6). The authors suggestedhyperresponsivity of the IgA system to infectious or food
that these changes were a reflection of a local hyperactiv-antigen. This, coupled with defective clearance, could
ity of the renin-angiotensin system in these IgAN pa-produce mesangial deposits and a renal inflammatory
tients [49].response. Tonsils, as a part of the systemic IgA system,
Maschio et al, in a multicenter, randomized, placebo-may act as activators of the IgA dysregulation seen in
controlled study in 39 patients with biopsy-proven IgAN,those patients. Tonsillectomy was shown to be associated
normal renal function, and hypertension, showed thatwith a decrease in proteinuria, hematuria, and serum
total IgA concentration, without any effect demon- angiotensin-converting enzyme inhibitors reduced pro-
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Table 6. Hypertension management
Follow-up Level of
Author [Reference] Design N Treatment months Results evidence
Coppo [49] NRCT 27 Captopril 26 ↑ GFR 4
Maschio [50] RCT 39 Fosinopril 9 ↓ Proteinuria 3
Cattran [51] NRCT 115 ACEI 29 ↑ GFR 4
↓ Proteinuria
Bannister [52] NRCT 23 Nifedipine 12 5GFR 2
vs. ACEI ↓ Proteinuria with ACEI
Abbreviations are: NRCT, non-randomized controlled trial; RCT, randomized controlled trial; ACEI, angiotensin-converting enzyme inhibitor; GFR, glomerular
filtration rate.
teinuria even in normotensive patients (level 3). The REFERENCES
follow-up period of three months was obviously too short 1. Berger J, Hinglais N: [Intercapillary deposits of IgA-IgG] Les
de´pots intercapillaires d’IgA-IgG. J Urol Nephrol 74:694–695, 1968to show changes in renal function [50].
2. Galla JH: IgA nephropathy. Kidney Int 47:377–387, 1995Cattran published a retrospective analysis comparing
3. Rodicio JL: Idiopathic IgA nephropathy. Kidney Int 25:717–729,
angiotensin-converting enzyme inhibitors in 27 patients 1984
4. Newell GC: Cirrhotic glomerulonephritis: Incidence, morphol-to other treatment in 55 and no treatment in 33 patients.
ogy, clinical features and pathogenesis. Am J Kidney Dis 9:183–190,The mean follow-up period was 29 months. Treatment
1987
with angiotensin-converting enzyme inhibitors resulted 5. Pasternack A, Collin P, Mustonen J, Reunala T, Rantala I,
Laurila K, Teppo AM: Glomerular IgA deposits in patients within a slower rate of decline in renal function as measured
celiac disease. Clin Nephrol 34:56–60, 1990by slope of creatinine clearance (20.4 ml/min/month vs.
6. Weiss JH, Bhathena DB, Curtis JJ, Lucas BA, Luke RG: A
21.0 ml/min/month) and a higher percentage of remis- possible relationship between Henoch-Scho¨nlein syndrome and
IgA nephropathy (Berger’s disease): An illustrative case. Nephronsion in proteinuria (18.5 vs. 1.8%, level 4 evidence) [51].
22:582–591, 1978Bannister et al reported in 1995 partial results from a
7. D’Amico G: The commonest glomerulonephritis in the world: IgA
prospective study in 23 hypertensive patients who had nephropathy. Q J Med 64:709–727, 1987
8. Levy M, Berger J: Worldwide perspective of IgA nephropathy.completed a year of follow-up, comparing nifedipine to
Am J Kidney Dis 12:340–347, 1988enalapril. There was no difference on the rate of decline 9. Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy,
of renal function in the two groups, but nifedipine had the most common glomerulonephritis worldwide: A neglected dis-
ease in the United States? Am J Med 84:129–132, 1988no favorable effect on proteinuria as opposed to angio-
10. Hoy WE, Hughson MD, Smith SM, Megill DM: Mesangial prolif-tensin-converting enzyme inhibitors (level 2) [52]. erative glomerulonephritis in southwestern American Indians. Am
J Kidney Dis 21:486–496, 1993
Other therapies 11. Schena FP: A retrospective analysis of the natural history of pri-
mary IgA nephropathy worldwide. Am J Med 89:209–215, 1990Several other treatments have been tried in IgAN. 12. Galla JH, Kohaut EC, Alexander R, Mestecky J: Racial differ-
Phenytoin, although it depresses the IgA level in serum, ence in the prevalence of IgA-associated nephropathies. Lancet 2:
522, 1984does not seem to have beneficial effects on the renal
13. Odum J, Peh CA, Clarkson AR, Bannister KM, Seymour AE,lesions [53]. Antiplatelet drugs [54], urokinase, danazol, Gillis D, Thomas AC, Mathew TH, Woodroffe AJ: Recurrent
sodium cromoglycate, dietary gluten restriction, and low- mesangial IgA nephritis following renal transplantation. Nephrol
Dial Transplant 9:309–312, 1994antigen-content diet have not been shown to influence
14. Silva FG, Chander P, Pirani CL, Hardy MA: Disappearance of
renal function [53]. glomerular mesangial IgA deposits after renal allograft transplanta-
tion. Transplantation 33:241–246, 1982Based on abnormalities in the IgA immune system
15. Lai FM, Li EK, Suen MW, Lui SF, Li PK, Lai KN: Pulmonaryand on the finding of a deficiency of IgG1 subclass in
hemorrhage: A fatal manifestation in IgA nephropathy. Arch Pa-
IgAN, a recent trial of high-dose immunoglobulin ther- thol Lab Med 118:542–546, 1994
16. Lai KN: The cellular immunity and nature of IgA molecules inapy proved successful in 11 patients with severe IgA or
IgA nephropathy. Contrib Nephrol 104:99–111, 1993Henoch-Scho¨nlein purpura when administered over nine
17. Rifai A, Small P Jr, Ayoub EM: Experimental IgA nephropathy:
months [55]. The decline of nearly 4 ml/min/month in Factors governing the persistence of IgA-antigen complexes in the
circulation of mice. Contrib Nephrol 40:37–44, 1984GFR was almost stopped, whereas hematuria and pro-
18. Jennette JC: The immunohistology of IgA nephropathy. Am Jteinuria decreased, over a 14 month follow-up. Relapse
Kidney Dis 12:348–352, 1988
appeared to be prompt if therapy was discontinued. Al- 19. Isaacs KL, Miller F: Role of antigen size and charge in immune
complex glomerulonephritis. Lab Invest 47:198–205, 1982though immunoglobulin may be an effective immunomo-
20. Rekola S, Bergstrand A, Bucht H: Deterioration of GFR indulatory treatment [56], prospective controlled trials are IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney
required. Int 40:1050–1054, 1991
21. Ibels LS, Gyory AZ: IgA nephropathy: Analysis of the natural
Reprint requests to Maryse Courteau, M.D., CHUM, Pavillon Notre- history, important factors in the progression of renal disease, and
a review of the literature. Medicine (Baltimore) 73:79–102, 1994Dame, 1560 Sherbrooke Est, Montre´al, Que´bec H2L 4M1, Canada.
Nolin and Courteau: IgA nephropathyS-62
22. Packham DK, Hewiston TD, Yan HD, Elliot CE, Nicholls K, young patients with immunoglobulin A nephropathy: Scientific
Planning Committee of the IgA Nephropathy Study. Am J KidneyBecker GJ: Acute renal failure in IgA nephropathy. Clin Nephrol
42:349–353, 1994 Dis 26:792–796, 1995
41. Goumenos D, Ahuja M, Shortland JR, Brown CB: Can immuno-23. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux
F: Prognostic factors in mesangial IgA glomerulonephritis: An exten- suppressive drugs slow the progression of IgA nephropathy?
Nephrol Dial Transplant 10:1173–1181, 1995sive study with univariate and multivariate analyses. Am J Kidney
Dis 18:12–19, 1991 42. Lai KN, Lai FM, Leung AC, Ho CP, Vallance-Owen J: Plasma
exchange in patients with rapidly progressive idiopathic IgA ne-24. Johnston PA, Brown JS, Braumholtz DA, Davison AM: Clinico-
pathological correlations and long-term follow-up in 253 United phropathy: A report of two cases and review of literature. Am J
Kidney Dis 10:66–70, 1987Kingdom patients with IgA nephropathy: A report from the MRC
glomerulonephritis registry. Q J Med 84:619–627, 1992 43. Nicholls K, Becker G, Walker R, Wright C, Kincaid-Smith P:
Plasma exchange in progressive IgA nephropathy. J Clin Apheresis25. Neelakantappa K, Gallo GR, Baldwin DS: Proteinuria in IgA
nephropathy. Kidney Int 33:716–721, 1988 5:128–132, 1990
44. Roccatello D, Ferro M, Coppo R, Mazzucco G, Quattrocchio26. Glassock RJ: IgA nephropathy: Report of a symposium down
under. Nephrol Dial Transplant 9:1341–1343, 1994 G, Piccoli G: Treatment of rapidly progressive IgA nephropathy.
Contrib Nephrol 111:177–183, 199527. Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA
nephropathy with nephrotic syndrome: A long-term controlled trial. 45. Be´ne´ MC, Hurault de Ligny B, Kessler M, Foliguet B, Faure
GC: Tonsils in IgA nephropathy. Contrib Nephrol 104:153–161, 1993Clin Nephrol 26:174–180, 1986
28. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama 46. Katafuchi R, Takebayashi S, Taguchi T: Hypertension-related
aggravation of IgA nephropathy: A statistical approach. ClinM: Steroid therapy in IgA nephropathy: A retrospective study in
heavy proteinuric cases. Nephron 48:12–17, 1988 Nephrol 30:261–269, 1988
47. Pogo A: Importance of action of angiotensin II in the glomerular29. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S: Steroid
therapy during the early stage of progressive IgA nephropathy: A growth of maturing kidneys. Kidney Int 38:1068–1074, 1990
48. Deleted in proof.10-year follow-up study. Nephron 72:237–242, 1996
30. Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee 49. Coppo R, Amore E, Gianoglio B, Cacare G, Picciotto G, Rocca-
tello D, Peruzzi L, Piccoli G, De Filippi PG: Angiotensin IIEJ, Pwee HS, Lim CH: Effects of triple therapy on the progression
of mesangial proliferative glomerulonephritis. Clin Nephrol 27:56– local hyperreactivity in the progression of IgA nephropathy. Am
J Kidney Dis 21:593–602, 199364, 1987
31. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH: Effects of triple 50. Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna
G, Sasdelli M, Zuccala` A, Zucchelli P: ACE inhibition reducestherapy in IgA nephritis: A follow-up study 5 years later. Clin
Nephrol 36:60–66, 1991 proteinuria in normotensive patients with IgA nephropathy: A
multicentre, randomized, placebo-controlled study. Nephrol Dial32. Walker RG, Yu SH, Owen JE, Kincaid-Smith P: The treatment of
mesangial IgA nephropathy with cyclophosphamide, dipyridamole Transplant 9:265–269, 1994
51. Cattran DC, Greenwood C, Ritchie S: Long-term benefits ofand warfarin: A two-year prospective trial. Clin Nephrol 34:103–
107, 1990 angiotensin-converting enzyme inhibitor therapy in patients with
severe immunoglobulin A nephropathy: A comparison to patients33. Lai KN, Lai FM, Li PK, Vallance-Owen J: Cyclosporin treatment
of IgA nephropathy: A short term controlled trial. BMJ 295:1165– with other antihypertensive agents and to patients receiving no
therapy. Am J Kidney Dis 23:247–254, 19941168, 1987
34. Holman RT, Johnson SB, Bibus D, Spencer DC, Doradio JV 52. Bannister KM, Weaver A, Clarrkson R, Woodroffe AJ: Effect
of angiotensin-converting enzyme and calcium channel inhibitionJr: Essential fatty acid deficiency profiles in idiopathic immuno-
globulin A nephropathy. Am J Kidney Dis 23:648–654, 1994 on progression in IgA nephropathy. Contrib Nephrol 111:184–193,
199535. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin
B, Diczfalusy U, Bjo¨rkhem I, Bergstro¨m J: Treatment of IgA 53. Clarkson AR, Woodroffe AJ, Bannister KM, Odum J, Thomas
A: Therapy in IgA nephropathy. Contrib Nephrol 104:189–197,nephropathy with omega-3 polyunsaturated fatty acids: A prospec-
tive, double-blind, randomized study. Clin Nephrol 41:183–190, 1993
54. Chan MK, Kwan SY, Chan KW, Yeung CK: Controlled trial of1994
36. Hamazaki T, Tateno S, Shishido H: Eicosapentaenoic acid and antiplatelet agents in mesangial IgA glomerulonephritis. Am J
Kidney Dis 9:417–421, 1987IgA nephropathy. Lancet 1:1017–1018, 1984
37. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA 55. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M,
Philippon C, Deforges L, Terzidis H, Intrator L, Andre C,nephropathy with eicosapentaenoic acid (EPA): A two-year pro-
spective trial. Clin Nephrol 31:128–131, 1989 Adnot S: High-dose immunoglobulin therapy for severe IgA ne-
phropathy and Henoch-Scho¨nlein purpura. Ann Intern Med38. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley
KE: A controlled trial of fish oil in IgA nephropathy: Mayo Ne- 120:476–484, 1994
56. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M,phrology Collaborative Group. N Engl J Med 331:1194–1199, 1994
39. Cheng IKP, Chan PCK, Chan MK: The effect of fish oil dietary Philippon C, Deforges L, Terzidis H, Intrator L, Andre C,
Adnot S, Bonin P, Bierling P, Remy P, Lagrue G, Lang P,supplements on the progression of mesangial IgAN. Nephrol Dial
Transplant 5:241–246, 1990 Weil B: Immunomodulation with low-dose immunoglobulins for
moderate IgA nephropathy and Henoch-Scho¨nlein purpura. Neph-40. Hogg RJ: A randomized, placebo-controlled, multicenter trial
evaluating alternate-day prednisone and fish oil supplements in ron 69:327–334, 1995
